Related Experiment Video
Updated: Mar 16, 2026
06:19
Comparison of Three Clinical Stereoscopic Methods for Measuring Binocular Visual Function During Amblyopic Treatment in Unilateral Amblyopia
Published on: September 27, 2024
617
The Ahmed Versus Baerveldt Study: Five-Year Treatment Outcomes
Panos G Christakis1, Jeffrey W Kalenak2, James C Tsai3
1Department of Ophthalmology and Vision Sciences, University of Toronto Faculty of Medicine, Toronto, Canada.
Ophthalmology
|August 22, 2016
Summary
The Baerveldt implant showed a lower failure rate and reduced intraocular pressure (IOP) more effectively than the Ahmed implant in glaucoma patients. However, the Baerveldt implant carried a small risk of hypotony.
Area of Science:
- Ophthalmology
- Surgical Innovation
- Glaucoma Management
Background:
- Glaucoma treatment often involves aqueous shunts to manage intraocular pressure (IOP).
- Two commonly used shunts are the Ahmed valve and the Baerveldt implant.
- Patient selection is critical for optimizing outcomes in refractory glaucoma.
Purpose of the Study:
- To compare the efficacy and safety of the Ahmed-FP7 valve implant versus the Baerveldt-350 implant for glaucoma treatment.
- To evaluate long-term outcomes, including intraocular pressure control, medication use, and surgical failure rates.
Main Methods:
- An international, multicenter, randomized trial involving 238 adult patients with uncontrolled glaucoma.
- Patients were randomized to receive either an Ahmed-FP7 or a Baerveldt-350 implant via standardized surgical techniques.
- Primary outcome was treatment failure, defined by IOP, vision loss, or reoperation; secondary outcomes included IOP, medication use, and complications.
Main Results:
- At 5 years, the Baerveldt group had a significantly lower cumulative failure rate (40%) compared to the Ahmed group (53%).
- The Baerveldt group achieved lower mean IOP and required fewer medications post-surgery than the Ahmed group.
- Hypotony was a complication in 4% of Baerveldt patients, whereas no hypotony was observed in the Ahmed group.
Conclusions:
- Both the Ahmed and Baerveldt implants effectively reduce IOP and medication dependence in glaucoma patients.
- The Baerveldt implant demonstrated superior efficacy in terms of failure rate and IOP reduction but posed a risk of hypotony.
- The choice between implants should consider the trade-off between efficacy and the risk of specific complications like hypotony.
